Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programs
Cash position expected to fund operations into second quarter of 2025
Two Phase 1 clinical trials of lead program, TIDAL-01, in several solid tumor Indications ongoing
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.